Li Watsek Analyst Performance

Biotech Analyst at Cantor Fitzgerald

Li Watsek is a stock analyst at Cantor Fitzgerald in the healthcare sector, covering 33 publicly traded companies. Over the past year, Li Watsek has issued 21 stock ratings, including buy and hold recommendations. While full access to Li Watsek's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Li Watsek's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
101 Last 5 Years
Buy Recommendations
94.44% 85 Buy Ratings
Companies Covered
33 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy5.6%5 ratings
Buy88.9%80 ratings
Hold5.6%5 ratings
Sell0.0%0 ratings

Out of 90 total stock ratings issued by Li Watsek at Cantor Fitzgerald, the majority (88.9%) have been Buy recommendations, followed by 5.6% Strong Buy and 5.6% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
84.8% of companies on NASDAQ
28 companies
NYSE
6.1% of companies on NYSE
2 companies
NYSEAMERICAN
3.0% of companies on NYSEAMERICAN
1 company
TSE
3.0% of companies on TSE
1 company
OTCMKTS
3.0% of companies on OTCMKTS
1 company

Li Watsek, an analyst at Cantor Fitzgerald, currently covers 33 companies listed on NASDAQ, NYSE, NYSEAMERICAN, TSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
33 companies
100.0%

Li Watsek of Cantor Fitzgerald specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
29 companies
87.9%
PHARMACEUTICALS
4 companies
12.1%

Li Watsek's Ratings History at Cantor Fitzgerald

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
11/13/2026Boost Price Target$267.07$315.00Overweight
Celcuity, Inc. stock logo
CELC
Celcuity
10/22/2026Initiated Coverage$61.56$140.00Overweight
Replimune Group, Inc. stock logo
REPL
Replimune Group
10/5/2026Reiterated Rating$13.23Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
9/25/2026Reiterated Rating$225.60$300.00Overweight
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
8/21/2026Initiated Coverage$6.86Overweight
Replimune Group, Inc. stock logo
REPL
Replimune Group
8/12/2026Reiterated Rating$14.90Overweight
Immuneering Corporation stock logo
IMRX
Immuneering
7/8/2026Initiated Coverage$5.10$17.00Overweight
Immuneering Corporation stock logo
IMRX
Immuneering
7/8/2026Initiated Coverage$5.10$17.00Overweight
Immuneering Corporation stock logo
IMRX
Immuneering
7/8/2026Initiated Coverage$5.53$17.00Overweight
Adlai Nortye Ltd. Sponsored ADR stock logo
ANL
Adlai Nortye
6/22/2026Initiated Coverage$10.10Overweight
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
6/4/2026Reiterated Rating$15.85Overweight
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
5/29/2026Initiated Coverage$17.59Overweight
Replimune Group, Inc. stock logo
REPL
Replimune Group
4/13/2026Downgrade$1.59Hold
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3/12/2026Reiterated Rating$5.28Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3/2/2026Reiterated Rating$236.07$300.00Overweight
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2/27/2026Lower Price Target$19.14$37.00Overweight
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2/24/2026Initiated Coverage$33.30Overweight
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2/18/2026Reiterated Rating$31.09Overweight
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
12/22/2025Initiated Coverage$22.40Overweight
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
12/3/2025Initiated Coverage$5.22Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
11/26/2025Reiterated Rating$206.65Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
10/13/2025Boost Price Target$209.55$254.00Overweight
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
10/2/2025Initiated Coverage$0.97Overweight
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
9/9/2025Reiterated Rating$23.39Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
8/8/2025Boost Price Target$183.27$203.00Overweight
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/30/2025Upgrade$7.53Overweight
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6/26/2025Reiterated Rating$5.75Overweight
Replimune Group, Inc. stock logo
REPL
Replimune Group
6/20/2025Initiated Coverage$9.49Overweight
Affimed stock logo
AFMD
Affimed
5/14/2025Downgrade$0.09Hold
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
5/12/2025Reiterated Rating$155.13$200.00Overweight
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
3/27/2025Reiterated Rating$33.91Overweight
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
3/26/2025Reiterated Rating$3.41Overweight
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3/14/2025Initiated Coverage$4.02Overweight
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3/4/2025Upgrade$2.35Strong-Buy
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
3/4/2025Upgrade$7.33Strong-Buy
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
3/4/2025Upgrade$35.59Strong-Buy
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2/25/2025Boost Price Target$152.43$200.00Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2/11/2025Reiterated Rating$118.94$170.00Overweight
Arvinas, Inc. stock logo
ARVN
Arvinas
2/7/2025Reiterated Rating$19.25Overweight
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
2/5/2025Upgrade$3.54Strong-Buy
Drop these 5 stocks before the market opens tomorrow! (Ad)

The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel

See the five stocks Weiss Ratings analysts are watching closely now.
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2/5/2025Upgrade$26.93Strong-Buy
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
1/31/2025Initiated Coverage$6.12Overweight
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
1/24/2025Reiterated Rating$1.50Overweight
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
1/13/2025Reiterated Rating$23.83Overweight
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
12/17/2024Reiterated Rating$26.05Overweight